A PHASE IIA, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY, SAFETY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF SELNOFLAST IN REDUCING VASCULAR INFLAMMATION IN PATIENTS WITH ATHEROSCLEROSIS AT RISK FOR MAJOR ADVERSE CARDIAC EVENTS

Registry ID

GC46102

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

GENENTECH INC

Start date

2026-02-13

Last update

2025-11-21

Conditions

• ATHEROSCLEROSIS

Related clinical trials

• NUANCE-ICAD: EFFECT OF GENOTYPE-GUIDED ORAL P2Y12 INHIBITOR SELECTION VS CONVENTIONAL CLOPIDOGREL THERAPY IN SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE: A PILOT PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT (PROBE) MULTI-CENTRE STUDY
• MINERALOCORTICOID RECEPTOR ANTAGONISM CLINICAL EVALUATION IN ATHEROSCLEROSIS

View on source registry